Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Active:	No
Cancer Type:	Breast Cancer Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer Prostate Cancer Solid Tumor Unknown Primary	NCT ID:	NCT04726332
Trial Phases:	Phase I	Protocol IDs:	XL102-101 (primary) NCI-2021-03620
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Exelixis Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT04726332

Summary

This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety,
tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally
alone and in multiple combination regimens to subjects with advanced solid tumors.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.